Published in Medical Letter on the CDC and FDA, June 28th, 2009
The Company expects this milestone to trigger its long-term plan to establish its platform as the 'one-stop bone-, tendon- and ligament-injectable, biodegradable adhesive technology' for surgeries at hospitals, clinics and other private surgical centers within the orthopedic industry.
"BSI's OsteoCrete™, now FDA-cleared for long-bone and pelvis...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA